TY - JOUR
T1 - Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) of prostate cancer
T2 - current and emerging applications
AU - Moran, Shamus
AU - Cheng, Heather H.
AU - Weg, Emily
AU - Kim, Eric H.
AU - Chen, Delphine
AU - Iravani, Amir
AU - Ippolito, Joseph E.
N1 - Publisher Copyright:
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024.
PY - 2024/4
Y1 - 2024/4
N2 - Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) is transforming the management of patients with prostate cancer. In appropriately selected patients, PSMA-PET offers superior sensitivity and specificity compared to conventional imaging (e.g., computed tomography and bone scintigraphy) as well as choline and fluciclovine PET, with the added benefit of consolidating bone and soft tissue evaluation into a single study. Despite being a newly available imaging tool, PSMA-PET has established indications, interpretation guidelines, and reporting criteria, which will be reviewed. The prostate cancer care team, from imaging specialists to those delivering treatment, should have knowledge of physiologic PSMA radiotracer uptake, patterns of disease spread, and the strengths and limitations of PSMA-PET. In this review, current and emerging applications of PSMA-PET, including appropriateness use criteria as well as image interpretation and pitfalls, will be provided with an emphasis on clinical implications. Graphical abstract: (Figure presented.)
AB - Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) is transforming the management of patients with prostate cancer. In appropriately selected patients, PSMA-PET offers superior sensitivity and specificity compared to conventional imaging (e.g., computed tomography and bone scintigraphy) as well as choline and fluciclovine PET, with the added benefit of consolidating bone and soft tissue evaluation into a single study. Despite being a newly available imaging tool, PSMA-PET has established indications, interpretation guidelines, and reporting criteria, which will be reviewed. The prostate cancer care team, from imaging specialists to those delivering treatment, should have knowledge of physiologic PSMA radiotracer uptake, patterns of disease spread, and the strengths and limitations of PSMA-PET. In this review, current and emerging applications of PSMA-PET, including appropriateness use criteria as well as image interpretation and pitfalls, will be provided with an emphasis on clinical implications. Graphical abstract: (Figure presented.)
KW - Imaging
KW - PET/CT
KW - PSMA
KW - Prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=85185695025&partnerID=8YFLogxK
U2 - 10.1007/s00261-024-04188-w
DO - 10.1007/s00261-024-04188-w
M3 - Review article
C2 - 38386156
AN - SCOPUS:85185695025
SN - 2366-004X
VL - 49
SP - 1288
EP - 1305
JO - Abdominal Radiology
JF - Abdominal Radiology
IS - 4
ER -